ARA 290 vs GHK-Cu
ARA 290 and GHK-Cu are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: ARA 290 is 11-amino-acid epo-derived linear peptide, while GHK-Cu is tripeptide-copper(ii) complex (gly-his-lys : cu²⁺) — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus sterile or bacteriostatic water); their leading degradation routes differ (asparagine/glutamine deamidation is the most plausible slow route for this sequence. for ARA 290, copper dissociation at acidic ph for GHK-Cu), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
ARA 290 — origin
ARA 290 (Cibinetide) is an 11-residue peptide modelled on the helix-B surface of erythropoietin. It was engineered to engage the innate repair receptor — a heteromer of the EPO receptor and the beta-common receptor — without the erythropoietic (red-blood-cell-stimulating) activity of full-length EPO.
GHK-Cu — origin
GHK was identified by Loren Pickart in 1973 as a factor in human plasma whose concentration declines markedly with age. The decisive later finding was that its activity depends on chelated copper(II) — the peptide and the metal function as a unit. GHK-Cu is therefore a coordination complex, not simply a peptide, and it is the only such compound in this catalogue.
ARA 290 research themes
Studied for selective engagement of the EPOR/beta-common receptor heteromer that mediates tissue-protective signalling, distinct from the classical erythropoietic receptor.
A substantial share of the published literature examines small-fibre and neuropathic-pain research models.
Investigated for modulation of inflammatory pathways in preclinical tissue-injury models.
GHK-Cu research themes
The best-populated area of the GHK-Cu literature, examined in dermal fibroblast models.
Studied for effects on the MMP/TIMP balance governing matrix turnover.
Copper itself is an angiogenic cofactor, and the complex is studied in that context.
Plasma GHK falls substantially between early and later adulthood, a finding central to research interest in the molecule.
ARA 290 handling
- Reach room temperature before opening the vial.
- Add diluent gently down the vial wall; do not vortex.
- Use low-bind labware at low working concentrations to limit adsorption.
GHK-Cu handling
- Never reconstitute in acidic diluent — low pH dissociates the copper complex.
- Keep chelating agents such as EDTA out of any buffer used with this compound.
- Treat colour change as a discard signal: clear blue is correct, pale or green is not.
- Avoid contact with reducing agents, which will reduce Cu(II) to Cu(I) and collapse the complex.
Both third-party tested
Every Popular Peptides batch of ARA 290 and GHK-Cu is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
ARA 290 reference
Related comparisons
ARA 290 and GHK-Cu are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.